HWA
TNXP icon

HCR Wealth Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

HCR Wealth Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31
Closed -$18.6K – 232
2024
Q1 		$18.6K Buy
+31
New +$33.4K ﹤0.01% 222
2021
Q4 		– Hold
0
– -$12K – 209
2021
Q3 		– Hold
0
– – – 196

Other funds holding TNXP

Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCR Wealth Advisors's TNXP Position: Q2 2024 in Review

HCR Wealth Advisors sold out of Tonix Pharmaceuticals (TNXP) in Q2 2024, closing a stake of 31 shares — an estimated $18.6K sold.

HCR Wealth Advisors first reported a position in TNXP in Q1 2024 and held it in 1 quarter. The position peaked at $18.6K in Q1 2024. 13 funds tracked by Wall St. Rank hold TNXP as of Q2 2024.

  • HCR Wealth Advisors reported no remaining Tonix Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • HCR Wealth Advisors sold 31 Tonix Pharmaceuticals shares in Q2 2024, an estimated $18.6K.
  • HCR Wealth Advisors first reported a position in Tonix Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • HCR Wealth Advisors's Tonix Pharmaceuticals position peaked at $18.6K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2024.

Based on HCR Wealth Advisors's 13F filing for Q2 2024, filed 7 Aug 2024.